Cartesian Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-130.3M | $-77.4M | $-219.7M | $35.4M | $-25.7M | $-68.9M | $-55.4M | $-65.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $2.4M | $1.2M | $700.0K | $700.0K | $600.0K | $600.0K | $700.0K | $1.0M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $10.5M | $6.6M | $22.5M | $11.2M | $7.7M | $5.4M | $5.2M | $5.7M |
| Net Cash from Operating Activities | $-73.9M | $-23.7M | $-51.2M | $-31.6M | $-60.4M | $34.9M | $-51.4M | $-59.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $5.5M | $9.1M | $206.0K | $1.2M | $1.1M | $815.0K | $47.0K | $884.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-5.5M | $-8.7M | $34.6M | $-15.0M | $-17.1M | $-741.0K | $229.0K | $25.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-8.1M | $168.4M | $-13.1M | $39.2M | $52.9M | $14.4M | $105.0M | $697.0K |
| Net Change in Cash | $-87.4M | $136.0M | $-29.8M | $-7.4M | $-24.6M | $48.5M | $53.9M | $-33.3M |
| Free Cash Flow | $-79.4M | $-32.8M | $-51.4M | $-32.8M | $-61.5M | $34.1M | $-51.5M | $-60.0M |